Gao has more than 25 years of experience in leading various functions including finance, audit, investment, project management, compliance and board office.
The clinical lab staff shortage has been an issue in the UK for years. Industry can close the gap and make the field more resilient with careful strategizing.
The ability to monitor biopharma processes in real time provides significant advantages in optimizing product quality with respect to multiple attributes.
Toxicological evaluation is important at every stage of HPAPI development and manufacturing—CDMOs help ensure new treatments are brought to market safely.
Agreement combines the capacity and capabilities of OBiO process development scientists with enabling platforms and support from Univercells Technologies.
Aims to address specific needs of companies dedicated to the production and manufacturing of biopharmaceuticals for other companies in the healthcare sector.
The lab will contain 48 workbenches with services that include mass spectrometry and ligand binding assays, flow cytometry, biomarkers, and cell culture.